Clinical Trials Logo

Clinical Trial Summary

This is a single-arm, real-world study in Chinese patients with extensive stage small cell lung cancer. The purpose of this study was to evaluate Trilaciclib's protection against chemotherapy-induced bone marrow suppression, the safety and the impact on the antitumor effects of the combination with chemotherapy in Chinese patients with ES-SCLC in the real world. Patients with ES-SCLC who already use or plan to use Trilaciclib will be invited to participate in the study. Data were collected from 28 days prior to initial chemotherapy (platinum/etoposide or topotecan systemic chemotherapy) after patients signed informed consent until patients died, dropped out of the study, lost to follow-up, informed withdrawal, or study termination. The end time of the study was defined as withdrawal of information, loss of follow-up or death of all enrolled patients, or 12 months after the last patient was enrolled, whichever happened earlier.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05071703
Study type Interventional
Source Jiangsu Simcere Pharmaceutical Co., Ltd.
Contact Yongxing Chen
Phone 0898-963399
Email [email protected]
Status Recruiting
Phase Phase 4
Start date June 2, 2021
Completion date March 15, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04790253 - PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study) Phase 3
Completed NCT01987232 - Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive Stage Small-cell Lung Cancer Phase 1/Phase 2
Recruiting NCT05002868 - Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a PARP Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors Phase 1
Not yet recruiting NCT04985851 - To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS. N/A
Not yet recruiting NCT05068232 - Durvalumab and Ablative Radiation in Small Cell Lung Cancer N/A
Recruiting NCT04947774 - Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer
Recruiting NCT04902885 - Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin Combined With Etoposide or Topotecan Phase 3
Recruiting NCT04894591 - To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
Recruiting NCT04878016 - A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC Phase 3
Recruiting NCT04675697 - Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer Phase 2